Retrospective analysis of the safety and efficacy of immune checkpoint inhibitors (CPI) among patients (pts) with pre-existing autoimmune disorders (AD) and renal cell carcinoma (RCC) or urothelial carcinoma (UC).
Publication
, Conference
Chanza, NM; Xie, W; Issa, M; Dzimitrowicz, HE; Tripathi, A; Beuselinck, B; Lam, ET; Zakharia, Y; Mckay, RR; Shah, S; Mortazavi, A ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
May 20, 2019
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2019
Volume
37
Issue
15
Location
Chicago, IL
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Chanza, N. M., Xie, W., Issa, M., Dzimitrowicz, H. E., Tripathi, A., Beuselinck, B., … Harshman, L. C. (2019). Retrospective analysis of the safety and efficacy of immune checkpoint inhibitors (CPI) among patients (pts) with pre-existing autoimmune disorders (AD) and renal cell carcinoma (RCC) or urothelial carcinoma (UC). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 37). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
Chanza, Nieves Martinez, Wanling Xie, Majd Issa, Hannah Elizabeth Dzimitrowicz, Abhishek Tripathi, Benoit Beuselinck, Elaine Tat Lam, et al. “Retrospective analysis of the safety and efficacy of immune checkpoint inhibitors (CPI) among patients (pts) with pre-existing autoimmune disorders (AD) and renal cell carcinoma (RCC) or urothelial carcinoma (UC).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 37. AMER SOC CLINICAL ONCOLOGY, 2019.
Chanza NM, Xie W, Issa M, Dzimitrowicz HE, Tripathi A, Beuselinck B, et al. Retrospective analysis of the safety and efficacy of immune checkpoint inhibitors (CPI) among patients (pts) with pre-existing autoimmune disorders (AD) and renal cell carcinoma (RCC) or urothelial carcinoma (UC). In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2019.
Chanza, Nieves Martinez, et al. “Retrospective analysis of the safety and efficacy of immune checkpoint inhibitors (CPI) among patients (pts) with pre-existing autoimmune disorders (AD) and renal cell carcinoma (RCC) or urothelial carcinoma (UC).” JOURNAL OF CLINICAL ONCOLOGY, vol. 37, no. 15, AMER SOC CLINICAL ONCOLOGY, 2019.
Chanza NM, Xie W, Issa M, Dzimitrowicz HE, Tripathi A, Beuselinck B, Lam ET, Zakharia Y, Mckay RR, Shah S, Mortazavi A, Harrison MR, Choueiri TK, Harshman LC. Retrospective analysis of the safety and efficacy of immune checkpoint inhibitors (CPI) among patients (pts) with pre-existing autoimmune disorders (AD) and renal cell carcinoma (RCC) or urothelial carcinoma (UC). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2019.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2019
Volume
37
Issue
15
Location
Chicago, IL
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences